Results 11 to 20 of about 227,071 (100)
Nano-Chemotherapy synergize with immune checkpoint inhibitor- A better option?
Frontiers in Immunology, 2022 Immune checkpoint inhibitor (ICI) is one of the most important tumor treatment methods. Although the therapeutic efficiency of immune checkpoint inhibitor mono-therapy is limited, the combination of chemotherapy plus immune checkpoint inhibitors has ...
Xinye Qian +5 more
doaj +1 more source
Journal of Hematology & Oncology, 2017 Adaptive immunity is critical for disease progression and modulates T cell (TC) and antigen-presenting cell (APC) functions. Three signals were initially proposed for adaptive immune activation: signal 1 antigen recognition, signal 2 co-stimulation or co-
Jin Dai +10 more
doaj +1 more source
Immune Checkpoint Inhibitors and Kidney Toxicity: Advances in Diagnosis and Management
Kidney Medicine, 2021 Immune checkpoint inhibitors are now approved for more than 50 indications, and increasing numbers of patients with advanced cancer are receiving immunotherapy.
Harish Seethapathy +2 more
doaj +1 more source
Cancer Biology & Medicine, 2015 Immune checkpoint inhibitors are increasingly drawing much attention in the therapeutic development for cancer treatment. However, many cancer patients do not respond to treatments with immune checkpoint inhibitors, partly because of the lack of tumor ...
Jennifer Kleponis +2 more
doaj +1 more source
OncoImmunology, 2021 Immune checkpoint therapy has resulted in minimal clinical response in many pediatric cancers. We sought to understand the influence of immune checkpoint inhibition using anti-PD-1 and anti-CTLA-4 antibodies individually, in combination, and after ...
Soheila Shirinbak +13 more
doaj +1 more source
Pulmonary Circulation, 2021 Immunologic risk factors contribute to endothelial dysfunction and development of pulmonary vascular disease. Immune checkpoint inhibitors, used as immunotherapies for malignancies, have a wide range of reported immune-related adverse events.
Ruben Mylvaganam +6 more
doaj +1 more source
Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
Frontiers in Oncology, 2021 Immunotherapy has emerged as the fifth pillar of cancer treatment alongside surgery, radiotherapy, chemotherapy, and targeted therapy. Immune checkpoint inhibitors are the current superheroes of immunotherapy, unleashing a patient’s own immune cells to ...
Remy Thomas +4 more
doaj +1 more source
Immune phenotypes of prostate cancer cells: Evidence of epithelial immune cell-like transition?
Asian Journal of Urology, 2016 Prostate cancers (PCa) have been reported to actively suppress antitumor immune responses by creating an immune-suppressive microenvironment. There is mounting evidence that PCas may undergo an ‘‘Epithelial Immune Cell-like Transition’’ (EIT) by ...
Dong Lin +5 more
doaj +1 more source
Clinical & Translational Immunology, 2020 Objectives New targets or strategies are needed to increase the success of immune checkpoint‐based immunotherapy for multiple myeloma (MM). However, immune checkpoint signals in MM microenvironment have not been fully elucidated. Here, we aimed to have a
Jinheng Wang +6 more
doaj +1 more source
Role of mitochondrial metabolism in immune checkpoint inhibitors-related myocarditis
Frontiers in Cardiovascular Medicine, 2023 BackgroundImmune checkpoint inhibitor-related myocarditis is the deadliest complication of immunotherapy. However, the underlying pathophysiological mechanisms of its occurrence and development remain unclear. Due to the long-term lack of effective early
Xin Zhang +8 more
doaj +1 more source